옵션 체인은 다양한 행사가격과 만기일에 대한 NuCana의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 NuCana에 대한 시장 심리를 평가합니다..

NuCana (NASDAQ:NCNA) 주식, 옵션 체인

NuCana

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

NuCana PLC

TRNR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

VLCN

FCEL

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and maintains $6 price target.

News

Price Target

Analyst Ratings

OCGN

Chardan Capital Maintains Buy on Ocugen, Maintains $6 Price Target

Chardan Capital analyst Matthew Barcus maintains Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Buy and lowers the price target from $14 to $12.

ZURA

Chardan Capital Maintains Buy on Zura Bio, Lowers Price Target to $12

Canaccord Genuity analyst Yuri Lynk upgrades Stantec (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STN#TSX">STN</a>) from Hold to Buy and raises the price target from C$125 to C$135.

Upgrades

TSX:STN

Canaccord Genuity Upgrades Stantec to Buy, Raises Price Target to C$135

Wells Fargo analyst Andrew Bauch maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $52 to $55.

AFRM

Wells Fargo Maintains Overweight on Affirm Holdings, Raises Price Target to $55

Loop Capital analyst Yun Kim maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Hold and raises the price target from $45 to $55.

Loop Capital Maintains Hold on Dynatrace, Raises Price Target to $55

GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) and Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) are the top five trending tickers on Stocktwits Friday. Here&#8217;s a look at what grabbed <a href="https://www.benzinga.com/trading-ideas/24/11/41856335/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-42">retail investors&#8217; attention.</a>
GME GM-Meme: GameStop tops the list this week. The stock moved on heavy volume and zero fundamentals Friday, as the original meme-stock tends to do. Keith Gill, a.k.a. Roaring Kitty, dumped his Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares at the <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">end of October </a>and GameStop has climbed steadily since.&nbsp;
SOFI Surges: SoFi shares have climbed 17%<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41847971/jim-cramer-this-tech-stock-is-a-buy-sofi-technologies-is-good"> this week</a> as investors hope for deregulation under a second Trump presidency. The stock pumped on heavy volume and ended the day more than 9% higher. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
TSLA For President: Tesla shares blasted higher after Donald Trump won the presidential election. Tesla CEO Elon Musk joined Trump several times on the campaign trail and may even be appointed to a position in the administration.&nbsp;
Investors may also consider Trump's EV and tariff policy beneficial to Tesla, as both could potentially reduce competition for the U.S.-based EV giant. The stock has been up 30% since Tuesday, and its market cap has <a href="https://www.benzinga.com/news/management/24/11/41856784/elon-musks-wealth-tops-300-billion-as-teslas-market-cap-soars-above-1-trillion">now reached </a>more than $1 trillion. 
SAVA: Cassava Sciences is a frequent flier on the Stocktwits trending list. HC Wainwright &amp; Co. analyst Vernon Bernardino reiterated Cassava Sciences as a Buy and maintained an ambitious price target of $116 on Friday. The stock is currently trading at just under $27. 
AVXL: Anavex Life Sciences rounds out the list as another heavily-shorted biotech stock that moved on heavy volume, despite a lack of news. According to data from Benzinga Pro, 21.78% of shares are being sold short, and the stock saw more than triple its average trading volume on Friday. 
GME, SOFI, TSLA, SAVA, AVXL Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, GameStop shares closed up 6.1% at $24.88, SoFi shares closed up 9.33% at $13.01, Tesla shares closed up 8.19% at $321.22, Cassava Sciences shares closed up 6.55% at $27.00 and Anavex Life Sciences shares ended the day up 21% at $9.24 on Friday.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Topics

Movers

General

AVXL

CHWY

SAVA

SOFI

TSLA

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?

Loop Capital analyst Alton Stump upgrades Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) from Hold to Buy and raises the price target from $419 to $559.

Loop Capital Upgrades Domino's Pizza to Buy, Raises Price Target to $559

Jones Trading analyst Jason Weaver maintains GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a Buy and raises the price target from $18.75 to $32.

Jones Trading Maintains Buy on GEO Group, Raises Price Target to $32

EF Hutton analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

CTSO

EF Hutton Maintains Buy on CytoSorbents, Maintains $10 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Outperform and raises the price target from $19 to $22.

WRBY

Telsey Advisory Group Maintains Outperform on Warby Parker, Raises Price Target to $22

Rosenblatt analyst Kevin Cassidy maintains Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) with a Buy and maintains $17 price target.

OUST

Rosenblatt Maintains Buy on Ouster, Maintains $17 Price Target

Rosenblatt analyst Catharine Trebnick maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Buy and maintains $45 price target.

Rosenblatt Maintains Buy on RingCentral, Maintains $45 Price Target

Rosenblatt analyst Catharine Trebnick maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Buy and raises the price target from $85 to $90.

FTNT

Rosenblatt Maintains Buy on Fortinet, Raises Price Target to $90

Planet 13 Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNH#OTC">PLNH</a>) reported Friday afternoon a strong revenue increase of 29.7% year-over-year for Q3 2024, reaching $32.2 million. The growth was fueled by the expansion into the Florida market and solid performance at its Illinois store. 
Despite the revenue boost, the company posted a net loss of $7.4 million; still a significant improvement from the $46.3 million net loss in Q3 2023.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Improved Margins&nbsp;</h3>
The company's gross profit rose to $16.7 million, up from $11.1 million in the same quarter last year. Gross margins also improved, reaching 51.9%, compared to 44.7% previously. Planet 13 attributed the margin growth to enhanced yields from cultivation and higher margin sales in <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a>.&nbsp;
Operating expenses dropped sharply by 66.4%, thanks to reduced impairment losses, signaling better cost management.
Read Also:<a href="https://www.benzinga.com/general/health-care/24/11/41843261/kentucky-gov-beshear-the-jury-is-no-longer-out-kentuckians-want-medical-cannabis"> Kentucky Gov. Beshear: &#8216;The Jury Is No Longer Out,&#8217; Kentuckians Want Medical Cannabis</a>
<h3 class="wp-block-heading">Adjusted EBITDA And Future Outlook</h3>
Planet 13 reported an adjusted EBITDA of $1.3 million, a substantial increase from $0.2 million in Q3 2023, highlighting improved operating leverage.&nbsp;
In spite of consumer spending challenges, co-CEO Bob Groesbeck<a href="https://www.globenewswire.com/us/news-release/2024/11/08/2977890/0/en/Planet-13-Announces-Q3-2024-Financial-Results.html"> pointed out </a>the strategic focus on cash flow and scaling its footprint.
"Despite Florida not moving forward with adult-use [cannabis legalization], we see a significant growth runway by expanding our store footprint and enhancing cultivation assets in the state. In addition to our<a href="https://www.benzinga.com/topic/florida-cannabis"> Florida operations</a>, we&#8217;re focused on driving growth by scaling our neighborhood store network and broadening the distribution of our HaHa edibles," said Larry Scheffler, co-CEO of Planet 13.
With $27.4 million in cash, up from $11.8 million at the end of 2023, Planet 13 is positioning itself for future growth. The company's expansion in Florida and recent acquisitions signal a commitment to broadening its market presence as it aims for profitability in 2025.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/11/41843751/canopy-growth-q2-net-revenue-drops-9-yoy-projects-positive-earnings-ahead">Canopy Growth: Q2 Net Revenue Drops 9% YoY, Projects Positive Earnings Ahead</a>

Cannabis

Earnings

Management

Markets

PLNH

Planet 13 Slashes Costs 66%: Revenue Grows, Losses Shrink — Is This The Turning Point?

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and raises the price target from $45 to $50.

FIVN

Rosenblatt Maintains Buy on Five9, Raises Price Target to $50

Rosenblatt analyst Barton Crockett maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Buy and lowers the price target from $48 to $46.

PINS

Rosenblatt Maintains Buy on Pinterest, Lowers Price Target to $46

Rosenblatt analyst Barton Crockett maintains Liberty Formula One Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Buy and raises the price target from $91 to $93.

FWONK

Rosenblatt Maintains Buy on Liberty Formula One Gr, Raises Price Target to $93

NuCana plunges despite trial setback for cancer drug

NuCana plunges amid trial setback for cancer drug

NuCana plunges after trial setback for cancer drug

Nucana (NCNA) has released an update. NuCana plc showcased positive results from its Phase 2 study of NUC-7738 in combination with pembrolizumab, o...

NuCana Reports Breakthrough in Resistant Melanoma Treatment

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00. The company'...

Oppenheimer Sticks to Their Buy Rating for Nucana (NCNA)

NuCana soars on positive data from mid-stage trial for its melanoma treatment

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company's shares closed yesterd...

Truist Financial Keeps Their Buy Rating on Nucana (NCNA)

Nucana (NCNA) has released an update. NuCana plc has announced the US Patent and Trademark Office granted a new patent for NUC-7738, a novel anti-c...

NuCana Secures US Patent for Promising Cancer Drug

Nucana (NCNA) has released an update. NuCana plc has updated its Prospectus Supplement to increase the maximum aggregate offering amount to $5.4 mi...

NuCana plc Enhances Offering to $5.4 Million

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nucana (NCNA – Research Report), with a price...

Truist Financial Sticks to Their Buy Rating for Nucana (NCNA)

NCNA

RHHBF

RHHBY

Health Care

Press Releases

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Announces Completion of ADS Ratio Change

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Comments

NuCana

NuCana (NCNA) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌